HC Wainwright Issues Pessimistic Estimate for ARQT Earnings

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) – Research analysts at HC Wainwright lowered their FY2026 earnings estimates for Arcutis Biotherapeutics in a research report issued to clients and investors on Thursday, November 5th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of $0.25 for the year, down from their prior forecast of $0.44. The consensus estimate for Arcutis Biotherapeutics’ current full-year earnings is $0.28 per share. HC Wainwright also issued estimates for Arcutis Biotherapeutics’ Q4 2026 earnings at $0.16 EPS, Q4 2027 earnings at $0.24 EPS, FY2027 earnings at $0.67 EPS, FY2028 earnings at $1.25 EPS, FY2029 earnings at $1.62 EPS and FY2030 earnings at $1.83 EPS.

Other equities research analysts have also issued research reports about the company. Jefferies Financial Group restated a “buy” rating and set a $39.00 price objective on shares of Arcutis Biotherapeutics in a research report on Thursday, October 8th. Morgan Stanley increased their target price on Arcutis Biotherapeutics from $34.00 to $38.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Needham & Company LLC set a $40.00 target price on Arcutis Biotherapeutics in a research report on Thursday, November 5th. Cantor Fitzgerald began coverage on Arcutis Biotherapeutics in a research note on Thursday, October 15th. They set an “overweight” rating and a $48.00 price target on the stock. Finally, TD Cowen boosted their price target on Arcutis Biotherapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. Eight equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Arcutis Biotherapeutics has a consensus rating of “Moderate Buy” and an average target price of $39.75.

Arcutis Biotherapeutics Trading Up 4.5%

NASDAQ ARQT opened at $27.39 on Monday. The company has a quick ratio of 2.66, a current ratio of 2.92 and a debt-to-equity ratio of 0.42. Arcutis Biotherapeutics has a twelve month low of $19.30 and a twelve month high of $34.80. The company has a market cap of $3.46 billion, a price-to-earnings ratio of 130.43 and a beta of 1.66. The business’s fifty day moving average is $27.28 and its 200 day moving average is $25.37.

Arcutis Biotherapeutics (NASDAQ:ARQT) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.12). Arcutis Biotherapeutics had a return on equity of 14.18% and a net margin of 5.88%. The company had revenue of $143.92 million for the quarter, compared to analyst estimates of $142.59 million.

Insider Transactions at Arcutis Biotherapeutics

In related news, EVP Masaru Matsuda sold 40,000 shares of the business’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $34.32, for a total value of $1,372,800.00. Following the sale, the executive vice president owned 111,289 shares of the company’s stock, valued at $3,819,438.48. The trade was a 26.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Terrie Curran sold 38,200 shares of the business’s stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $25.03, for a total transaction of $956,146.00. Following the completion of the sale, the director directly owned 23,526 shares in the company, valued at approximately $588,855.78. This represents a 61.89% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 108,932 shares of company stock worth $3,158,225. 9.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ARQT. Montanova Capital LLC lifted its holdings in Arcutis Biotherapeutics by 0.9% during the 2nd quarter. Montanova Capital LLC now owns 12,437,000 shares of the company’s stock worth $326,098,000 after buying an additional 110,000 shares during the period. BlackRock Inc. acquired a new stake in shares of Arcutis Biotherapeutics in the second quarter valued at about $276,502,000. Bank of America Corp DE acquired a new stake in shares of Arcutis Biotherapeutics in the second quarter valued at about $78,330,000. Janus Henderson Group PLC raised its position in shares of Arcutis Biotherapeutics by 1.3% during the first quarter. Janus Henderson Group PLC now owns 1,854,566 shares of the company’s stock worth $43,684,000 after acquiring an additional 24,505 shares during the last quarter. Finally, Jupiter Topco LLC bought a new position in shares of Arcutis Biotherapeutics during the second quarter worth about $36,989,000.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics is a biopharmaceutical company focused on developing and commercializing treatments for inflammatory skin diseases. Founded in 2016, the company is headquartered in Westlake Village, California. Arcutis primarily serves the U.S. market and continues to develop medicines for dermatologic conditions. Its leadership is headed by President and Chief Executive Officer Frank Watanabe.